Neurim begins enrolment in Phase II trial of piromelatine to treat mild Alzheimer ’s disease

Israeli drug-development firm Neurim Pharmaceuticals has begun enrolling patients in its Phase II recognition study of piromelatine for mild Alzheimer ’s disease (AD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news